Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.

  title={Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.},
  author={John Danesh and Sarah Lewington and Simon G Thompson and Gordon D. O. Lowe and Rory Collins and John B. Kostis and A. C. Wilson and Aaron R. Folsom and K. K. Wu and Michal Benderly and Uri Goldbourt and Johann Willeit and Stefan Kiechl and John W. G. Yarnell and Peter M. Sweetnam and Peter C. Elwood and Mary Cushman and Bruce M. Psaty and Russell P. Tracy and Anne Tybjaerg-hansen and Frits Haverkate and Moniek P. M. de Maat and Francis Gerry R Fowkes and A. J. Lee and Felicity B Smith and Veikko V Salomaa and Kennet Harald and Renata Rasi and Elina M. Vahtera and Pekka Jousilahti and Juha Pekkanen and Ralph B. D'Agostino and William B. Kannel and Peter W. F. Wilson and Geoffrey H Tofler and Carmen Luisa Arocha-Pi{\~n}ango and A. Rodriguez-Larralde and Elena Nagy and Mercedes Elena Mijares and Ra{\'u}l A Espinosa and E Rodriquez-Roa and Elena Ryder and Mar{\'i}a Diez‐Ewald and Gilberto Campos and Virginia Fern{\'a}ndez and Enrique Torres and Roberto Marchioli and Franco Valagussa and Annika Rosengren and Lars W. Wilhelmsen and Georgios Lappas and Henry Eriksson and Peter Cremer and Dorothea Nagel and J. David Curb and Beatriz L. Rodr{\'i}guez and Katsuhiko Yano and Jukka T. Salonen and Kristiina Nyyssönen and Tomi-Pekka Tuomainen and Bo Hedblad and Peter Lind and Hannelore Loewel and Wolfgang Koenig and Tom W. Meade and Jackie A. Cooper and Bianca L. De Stavola and C. Knottenbelt and George J. Miller and Kenneth A. Bauer and Robert D. Rosenberg and S. Sato and Akihiko Kitamura and Yoshihiko Naito and Timo Palosuo and Pierre Ducimetiere and Philippe Amouyel and Dominique Arveiler and Alun E. Evans and Jean Ferri{\`e}res and I Juhan-vague and Annie Bingham and Helmut Schulte and Gerd Assmann and Bernard Cantin and Beno{\^i}t Lamarche and Jean-Pierre Despr{\'e}s and Gilles R. Dagenais and Hugh Tunstall-Pedoe and Mark Woodward and Yoav Ben-Shlomo and George Davey Smith and V. Palmieri and Jeunliang Yeh and Alicja Regina Rudnicka and Paul M. Ridker and Francesco Rodeghiero and Alberto Tosetto and James Shepherd and Ian Ford and Michele Robertson and Eric J. Brunner and M J Shipley and Edith J. M. Feskens and Daan Kromhout and Alfred Dickinson and Belinda K Ireland and Kelsey Juzwishin and Stephen Kaptoge and Sarah Lewington and Anis Memon and Nadeem Sarwar and Matthew Walker and Jeremy G. Wheeler and Ian R. White and Angela M. Wood},
  volume={294 14},
CONTEXT Plasma fibrinogen levels may be associated with the risk of coronary heart disease (CHD) and stroke. OBJECTIVE To assess the relationships of fibrinogen levels with risk of major vascular and with risk of nonvascular outcomes based on individual participant data. DATA SOURCES Relevant studies were identified by computer-assisted searches, hand searches of reference lists, and personal communication with relevant investigators. STUDY SELECTION All identified prospective studies… 

Figures and Tables from this paper

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Under a wide range of circumstances, there are continuous, independent, and modest associations of Lp(a) concentration with risk of CHD and stroke that appear exclusive to vascular outcomes.

Blood fibrinogen level as a biomarker of adverse outcomes in patients with coronary artery disease: A systematic review and meta-analysis

Elevated fibrinogen level is significantly associated with an increased risk of cardiovascular and all-cause mortality in patients with CAD and can serve as a promising biomarker for risk stratification of CAD.

Associations between fibrinogen levels and the risk of cardiovascular disease and all-cause death: a cohort study from the Chin-Shan community in Taiwan

Fibrinogen may be a potential risk factor for CAD but not for stroke, and further studies are necessary to clarify the differences in the role of fibr inogen levels on the risk of CVD between Asian and Western countries.

Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration.

Fibrinogen levels increased with age and showed continuous, approximately linear relations with several risk markers and slightly curvilinear associations with log triglycerides, albumin, and tobacco and alcohol consumption.

Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial

There is a small effect of FVIIc on CHD, after adjustment for age and trial treatment, but no association independent of other risk factors.

Meta-Analysis Associations of Plasma Fibrinogen Levels with Established Cardiovascular Disease Risk Factors, Inflammatory Markers, and Other Characteristics: Individual Participant Meta-Analysis of 154,211 Adults in 31 Prospective Studies

  • Medicine
  • 2007
Fibrinogen levels increased with age and showed continuous, approximately linear relations with several risk markers and slightly curvilinear associations with log triglycerides, albumin, and tobacco and alcohol consumption.

Fibrinogen and future cardiovascular disease in people with diabetes: Aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies

The associations of fibrinogen with CVD and all-cause mortality are broadly similar in people with and without diabetes status, and improvement in predictive accuracy after adding fibr inogen to established risk factors is not clinically important.



Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group.

It is indicated clearly that fibrinogen level is associated with significantly increased mortality in CHD patients and implementation of a standardized measuring method is required to allow assessment of risk inCHD patients on the basis of fibr inogen levels.

Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease

  • J. KostisAngela Wilson D. Kromhout
  • Medicine
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
  • 2004
The Fibrinogen Studies Collaboration will aim to characterize more precisely than has previously been possible the strength and shape of the age- and sex-specific associations of plasma fibr inogen with coronary heart disease and, where data are sufficient, with other vascular diseases.

Fibrinogen Concentration and Risk of Ischemic Stroke and Acute Coronary Events in 5113 Patients With Transient Ischemic Attack and Minor Ischemic Stroke

Risks of recurrent ischemic stroke and acute coronary events increase linearly with fibrinogen levels, but the relationships are weaker than in some previous population-based studies.

Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study.

In a population-based sample of adults without clinical evidence of coronary artery disease at baseline, fibrinogen levels predicted cardiovascular events independent of traditional risk factors, left ventricular hypertrophy, elevated arterial stiffness, and subnormal myocardial systolic function.

Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.

In older men and women, increased coagulation activity and disturbed fibrinolysis are predictors of future vascular events (both IHD and stroke), and plasma fibrinogen was independently related to risk of stroke in multivariate analysis.

The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study.

It is concluded that, if confirmed in other studies, the measurement of fibrinogen and/or factor VIII may help identify older individuals at higher risk for CVD events and mortality.

Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study).

Fibrinogen as a risk factor for stroke and myocardial infarction.

Although causality cannot be inferred from these data, it is possible that the fibrinogen level plays an important part in the development of stroke and myocardial infarction.